is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Learning never stops in the world of pharma. To make sure you’re up to date on all the latest developments in the industry, we will be bringing you more than 30 hours of free conference content at CPhI North America. Three theaters - Drug Development & Delivery, Drug Manufacturing (which will be part of the show floor) and BioProduction - will host sessions on these three different tracks. The conference sessions are free to attend for all registered visitors.
This year, the Women in Leadership Forum (WiLF) tackles an important aspect of leadership – empathy. Leaders in the pharma industry will share key moments from their leadership journey that demonstrate the importance of empathy. Ask questions and get to know the speakers better through this session! The cost to participate in this interesting and informative forum is only $60.
Drug manufacturing is one of the key areas where the pharma industry can potentially reduce cost and improve quality.
To learn more about the latest trends in this area, visit the Drug Manufacturing theater, which will be a part of the show floor at CPhI North America. The conference sessions will focus on:
and several other topics relevant to drug manufacturing. So if this is your area of interest, make sure you visit the theater for some great content.
What does the future hold for drug development & delivery? While the focus is on developing novel therapies, how are companies balancing this with efficiency and patient centricity?
Visit the Drug Development & Delivery theater, which will be a part of the show floor at CPhI North America to hear from thoughts leaders at Pfizer, AbbVie, BASF, Catalent, IQVIA, Lonza, Nelson Labs and Patheon Thermo Fisher on the key topics in this space, including:
… and many more.
Biopharma comprises 25% of the total pharma market and revenues have gone up by over 6000% from the 1990s to earlier this year. Pharma companies have shifted focus to complex therapies like biologics and cell & gene therapies, requiring more innovative biomanufacturing processes to speed up development.
If this is your area of interest why not visit the BioProduction theater at CPhI North America? Some of the topics include:
…and many more!
The new decade has rolled in, bringing new and unprecedented challenges. New products with shorter lifecycles, aging population and rigorous regulatory scrutiny will play a role in shaping the industry. In this article, leading industry experts in the region share their views on what the most important trends will be for this year, and this decade
How is biopharma striking a balance between modernizing drug development & delivery and the effort to rein in R&D expenses? While change is unlikely to be quick, there is consensus that pharma does need to embrace changes in drug development and delivery fully explore the wide range of opportunities that exist.
Biopharma comprises 25% of the total pharma market and revenues have gone up by over 6000% from the 1990s to now. What are companies doing to keep up with this growth and innovation? Read this article to find out.
Is the pharma industry making the most of AI’s potential when it comes to accelerating and enhancing pharmaceutical drug development? The utilisation of artificial intelligence (AI) by the pharmaceutical industry is gathering pace rapidly. The technology has evolved beyond simple neural networks and machine learning towards a deep learning approach geared at producing insights which should in theory enable better business decision making.
Pipeline diversification, emerging therapies and shifting customer demands are the real dynamics reshaping the contract manufacturing market, according to experts. Almost every article written about contracting reports that demand for outsourced manufacturing services is growing and states that the CDMO sector is consolidating.
FDA approval of GW Pharmaceuticals’ Epidiolex® is widely considered to be a landmark in cannabinoid-derived drug development. Not only is Epidiolex® the first FDA-approved drug that contains a purified drug substance (cannabidiol) derived from the Cannabis sativa plant (marijuana), but it is also the first FDA approved drug for the treatment of patients with a rare and severe form of childhood epilepsy, Dravet syndrome.
What role does empathy play in building successful teams, and in turn, businesses? Read on to find out how empathetic leadership promotes a strong corporate culture, and lays a strong foundation for success.
Global Pharma Insights is a new dedicated platform providing news, features, interviews and in-depth analysis on issues impacting pharmaceutical supply chains. From drug discovery and development to manufacturing and delivery, we bring you impactful content to keep you informed and help drive your business forward.